蛋白质工程市场－全球产业规模、份额、趋势、机会及预测（依产品类型、技术、最终用户、地区及竞争格局划分，2021-2031年）

全球蛋白质工程市场预计将从 2025 年的 31.4 亿美元大幅成长至 2031 年的 64.2 亿美元，复合年增长率达 12.66%。

该领域专注于系统性地改造蛋白质结构，以创造具有最佳化特性（例如触媒活性、特异性和稳定性）的新型分子。推动此领域发展的主要因素是：对重组疗法和单株抗体的需求不断增长，这些疗法和抗体可用于治疗自体免疫疾病和癌症等慢性疾病；以及利用工程酶进行永续生物製造的趋势。欧洲製药工业协会联合会 (EFPIA) 的报告也体现了这种对创新的坚定承诺，该报告指出，到 2024 年，欧洲以研发为基础的製药业将在研发方面投入约 550 亿欧元。

儘管存在这些积极迹象，但市场仍面临着与新型生物製药开发固有的高技术复杂性和营运成本相关的重大障碍。确保蛋白质稳定性并避免免疫抗原性需要复杂的製程，这会延长开发週期并增加资金需求。此外，产品核可中严格且不断变化的监管环境也可能导致额外的延误，显着增加中小型生物技术公司的进入门槛，并可能减缓市场整体成长速度。

市场驱动因素

机器学习和人工智慧的融合正在以前所未有的精度和速度实现从头设计，从而变革蛋白质工程领域。这些计算工具使研究人员能够在物理合成之前预测复杂的蛋白质结构并优化其功能特性，例如稳定性和结合亲和性。透过减少对传统人工筛检技术的依赖，这项技术加速了针对特定生物标的设计的分子的建构。这种协同效应的商业性前景正在推动大量投资；例如，Xaira Therapeutics 于 2024 年 4 月宣布已获得超过 10 亿美元的资金筹措，用于建立一个以人工智慧为中心的平台，致力于重新设计药物发现流程。

同时，全球对用于治疗慢性疾病的重组蛋白和单株抗体的需求不断增长，正推动着生产能力的显着扩张。随着代谢性疾病和自体免疫疾病的日益增多，製药开发商正致力于大规模生产工程化生物製药，这些製剂相比小分子药物具有更高的特异性。这一趋势体现在为保障供应链而进行的大规模基础设施投资。例如，诺和诺德在2024年6月宣布，将投资41亿美元在北卡罗来纳州克莱顿新建一座注射生产设施。同样，Astra Zeneca于2024年宣布，将投资3亿美元新建一座专注于下一代生物製剂和细胞疗法的生产设施，以确保未来的产能。

市场挑战

全球蛋白质工程市场的发展受到高昂营运成本和技术复杂性的严重限制，而这些成本和技术复杂性是开发新型生物製药的关键所在。实现必要的蛋白质稳定性并防止免疫抗原性需要专门的基础设施和广泛的研究，这导致开发週期长、资本支出巨大。这种资源密集型环境设定了很高的进入门槛，使得中小型生物技术公司难以有效参与竞争，也难以透过严格而漫长的监管核准流程来维持业务。

这些资金限制直接阻碍了市场扩张，因为它们限制了成功商业化的创新计划数量。近期投资趋势表明，新兴产业参与者的资金筹措大幅缩减，这凸显了这种压力的严重性。根据生技创新组织（BIO）的数据显示，生技Start-Ups的资金筹措从2025年第一季的26亿美元骤降至第二季的仅9亿美元。Start-Ups可用资金的减少限制了该产业推出新型重组蛋白疗法的能力，从而减缓了整个产业的成长速度。

市场趋势

与传统的单株抗体开发模式不同，製药业正日益专注于开发多特异性和双特异性抗体。为了更精准地治疗异质性固态肿瘤，研发人员越来越多地利用蛋白质工程技术来建构复杂的治疗模式，例如能够同时结合两种或多种不同抗原的T细胞衔接器。这种朝向多标靶架构的转变，能够引导免疫效应细胞标靶肿瘤部位，进而增强肿瘤治疗效果，而生物製药则不具备这种能力。这些专业平台的高价值也反映在策略收购中。例如，默克公司于2024年1月宣布，将以约6.8亿美元的以金额为准收购Harpoon Therapeutics，以整合该公司的三特异性抗体技术。

同时，市场正显着多元化发展，拓展至环境和工业酵素应用领域，使其重要性超越了医药应用。蛋白质工程在循环经济中正变得至关重要，尤其是在设计高性能酵素以降解和回收合成纤维和塑胶方面。这种方法将重点从合成转移到材料降解和废弃物化利用，从而支持包装和消费品行业的永续性目标。这项产业转型得到了大规模资本计划的推动。例如，Calbios于2024年4月启动了全球首个工业PET生物回收工厂，预计投资金额达2.3亿欧元，凸显了工程酶在环境管理领域的商业性潜力。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球蛋白质工程市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品类型（胰岛素、单株抗体、凝血因子{血液因子+组织型胞浆素原}、疫苗、生长因子{荷尔蒙+细胞激素}、其他产品类型）
  • 按技术划分（非理性蛋白质设计与理性蛋白质设计）
  • 以最终用户（製药和生物技术公司、学术机构、合约研究组织 {CRO}）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美蛋白质工程市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲蛋白质工程市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区蛋白质工程市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲蛋白质工程市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲蛋白质工程市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球蛋白质工程市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Agilent Technologies Inc.
• Amgen Inc.
• Bruker Corporation
• Bio-Rad Laboratories Inc.
• Eli Lilly and Company
• Merck KGaA
• Novo Nordisk AS
• PerkinElmer Inc.
• Thermo Fisher Scientific Inc.
• Waters Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Protein Engineering Market is projected to expand significantly, rising from a valuation of USD 3.14 Billion in 2025 to USD 6.42 Billion by 2031, reflecting a compound annual growth rate of 12.66%. This field centers on the systematic modification of protein structures to create novel molecules with optimized traits, such as enhanced catalytic activity, specificity, or stability. Growth is largely fueled by the rising need for recombinant therapeutics and monoclonal antibodies to manage chronic diseases like autoimmune disorders and cancer, alongside a shift toward sustainable biomanufacturing using engineered enzymes. This strong commitment to innovation is evidenced by the European Federation of Pharmaceutical Industries and Associations, which reported that the research-based pharmaceutical sector in Europe invested approximately €55 billion in R&D during 2024.

Despite these positive indicators, the market encounters substantial obstacles related to the high technical complexity and operational costs inherent in developing new biologics. Ensuring protein stability while avoiding immunogenicity necessitates intricate processes that prolong development schedules and increase capital requirements. Furthermore, navigating strict and changing regulatory landscapes for product approval poses additional delays, creating significant barriers to entry for smaller biotechnology firms and potentially retarding the overall pace of market growth.

Market Driver

The incorporation of machine learning and artificial intelligence is transforming the protein engineering sector by facilitating de novo design with unprecedented accuracy and speed. These computational tools enable researchers to forecast complex protein structures and refine functional characteristics, such as stability and binding affinity, prior to physical synthesis. By diminishing the reliance on conventional, labor-heavy screening techniques, this technology expedites the creation of molecules designed for specific biological targets. The commercial promise of this synergy is driving significant investment; for instance, Xaira Therapeutics announced in April 2024 that it had secured over $1 billion in committed capital to establish an AI-centric platform dedicated to redesigning drug discovery.

Concurrently, the rising global requirement for recombinant proteins and monoclonal antibodies to treat chronic conditions is driving a major expansion in manufacturing capabilities. As metabolic and autoimmune diseases become more prevalent, pharmaceutical developers are focusing on the scalable production of engineered biologics that provide better specificity compared to small-molecule drugs. This trend is highlighted by substantial infrastructure investments to secure supply chains, such as Novo Nordisk's June 2024 announcement of a $4.1 billion investment in a new injectable treatment facility in Clayton, North Carolina. Similarly, in 2024, AstraZeneca committed $300 million to a new site dedicated to next-generation biologics and cell therapy to ensure adequate future capacity.

Market Challenge

The Global Protein Engineering Market is significantly hindered by the substantial operational expenses and technical intricacies involved in creating novel biologics. Achieving necessary protein stability and preventing immunogenicity demands specialized infrastructure and extensive research, leading to prolonged development timelines and steep capital expenditures. This resource-intensive environment establishes a formidable barrier to entry, making it challenging for smaller biotechnology companies to compete effectively or maintain operations throughout the rigorous and lengthy regulatory approval process.

These financial constraints directly impede market expansion by limiting the volume of innovative projects that successfully reach commercialization. The severity of this pressure is illustrated by recent trends in investment, which indicate a sharp contraction in funding available for emerging industry players. According to the Biotechnology Innovation Organization, biotech startup funding fell precipitously from $2.6 billion in the first quarter of 2025 to just $900 million in the second quarter. This reduction in accessible capital for startups restricts the industry's ability to introduce new engineered protein therapies, thereby slowing the overall growth trajectory of the sector.

Market Trends

There is a growing industry focus on engineering multispecific and bispecific antibodies, a trend that distinguishes the current market from standard monoclonal antibody development. Developers are increasingly leveraging protein engineering to construct complex modalities, such as T-cell engagers, capable of binding simultaneously to two or more distinct antigens to improve therapeutic precision against heterogeneous solid tumors. This move toward multi-targeting architectures enhances oncological efficacy by directing immune effector cells straight to tumor sites, a function not found in traditional biologics. The high value placed on these specialized platforms is reflected in strategic acquisitions, such as Merck's January 2024 agreement to acquire Harpoon Therapeutics for an equity value of approximately $680 million to incorporate its trispecific antibody technologies.

In parallel, the market is diversifying significantly into environmental and industrial enzyme applications, extending the sector's relevance beyond pharmaceutical uses. Protein engineering is becoming essential for the circular economy, particularly in designing high-performance enzymes that depolymerize synthetic fibers and plastics for recycling. This approach shifts the focus from synthesis to material degradation and waste valorization, supporting sustainability objectives in packaging and consumer goods. This industrial shift is backed by substantial capital projects, such as Carbios' advancement in April 2024 of the world's first industrial PET biorecycling plant, representing an estimated investment of €230 million and highlighting the commercial potential of engineered enzymes in environmental management.

Key Market Players

• Agilent Technologies Inc.
• Amgen Inc.
• Bruker Corporation
• Bio-Rad Laboratories Inc.
• Eli Lilly and Company
• Merck KGaA
• Novo Nordisk AS
• PerkinElmer Inc.
• Thermo Fisher Scientific Inc.
• Waters Corporation

Report Scope

In this report, the Global Protein Engineering Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Protein Engineering Market, By Product Type

• Insulin
• Monoclonal Antibodies
• Coagulation Factors {Blood Factors + Tissue Plasminogen}
• Vaccines
• Growth Factors {Hormones + Cytokine}
• Other Product Types

Protein Engineering Market, By Technology

• Irrational Protein Design
• Rational Protein Design

Protein Engineering Market, By End User

• Pharmaceutical and Biotechnology Companies
• Academic Institutions
• Contract Research Organizations {CROs}

Protein Engineering Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Protein Engineering Market.

Available Customizations:

Global Protein Engineering Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Protein Engineering Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Insulin, Monoclonal Antibodies, Coagulation Factors {Blood Factors + Tissue Plasminogen}, Vaccines, Growth Factors {Hormones + Cytokine}, and Other Product Types)
  • 5.2.2. By Technology (Irrational Protein Design and Rational Protein Design)
  • 5.2.3. By End User (Pharmaceutical and Biotechnology Companies, Academic Institutions, and Contract Research Organizations {CROs})
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Protein Engineering Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Technology
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Protein Engineering Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Protein Engineering Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Protein Engineering Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By End User

7. Europe Protein Engineering Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Technology
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Protein Engineering Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By End User
  • 7.3.2. France Protein Engineering Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Protein Engineering Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Protein Engineering Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Protein Engineering Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By End User

8. Asia Pacific Protein Engineering Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Technology
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Protein Engineering Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By End User
  • 8.3.2. India Protein Engineering Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Protein Engineering Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Protein Engineering Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Protein Engineering Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By End User

9. Middle East & Africa Protein Engineering Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Technology
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Protein Engineering Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Protein Engineering Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Protein Engineering Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By End User

10. South America Protein Engineering Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Technology
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Protein Engineering Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Protein Engineering Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Protein Engineering Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Protein Engineering Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agilent Technologies Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Amgen Inc.
• 15.3. Bruker Corporation
• 15.4. Bio-Rad Laboratories Inc.
• 15.5. Eli Lilly and Company
• 15.6. Merck KGaA
• 15.7. Novo Nordisk AS
• 15.8. PerkinElmer Inc.
• 15.9. Thermo Fisher Scientific Inc.
• 15.10. Waters Corporation

16. Strategic Recommendations

17. About Us & Disclaimer